Drugs / meprogesterone acetate
last change Apr 2025 re-read 2 minutes ago

meprogesterone acetate

Developed for
endometrial cancer
Investigated by
Fudan University

Trials 1 · a red edge is where a trial was stopped

20262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT06914297 Apr 2025 → Oct 2027 expected endometrial cancer Fudan University Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as meprogesterone acetate meprogesterone acetate (MA, 160 mg qdpo)” NCT06914297
Route Oral “meprogesterone acetate (MA, 160 mg qdpo)” NCT06914297